Drug Trial Radar · NCT07370207
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Mar 6, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- AusperBio Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).
Conditions
- Hepatitis B, Chronic
Interventions
AHB-137Drug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with sustained response post AHB-137 treatmentTime frame: 24 Weeks post AHB-137 treatment
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Queen Mary Hospital - PPDS
Hong Kong, China · Recruiting
Japanese Red Cross Musashino Hospital
Musashino, Tokyo, Japan · Recruiting
National Center for Global Health and Medicine
Shinjuku-Ku, Tokyo, Japan · Recruiting
New Zealand Clinical Research
Grafton, Auckland, New Zealand · Recruiting
National University Hospital - Singapore
Singapore, Singapore · Recruiting
Chiayi Christian Hospital
Chiayi City, Taiwan · Recruiting
E-DA Hospital
Kaohsiung City, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.